REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical va...
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT06173037
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT06155396
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳Beijing Obstetrics and Gynecology Hospital ,Capital Medical University, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Conditions
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06155383
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳Shandong Cancer Hospital & Institute, Jinan, Shangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Registration Number
- NCT06105008
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
🇨🇳Binghe Xu, Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
🇨🇳Hunan Cancer Hospital, Changsha, China
A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT06038396
- Locations
- 🇨🇳
hongshan Hospital Affiliated to Fudan University, Shanghai, China
A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT06016062
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Qilu Hospital of shangdong university, Jinan, Shangdong, China
🇨🇳Jinan Central Hospital, Jinan, Shandong, China
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT05980481
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05943379
- Locations
- 🇨🇳
Peking University First Hosptital, Beijing, Beijing, China
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05940896
- Locations
- 🇨🇳
Shandong Cancer hospital &Institute, Jinan, Shandong, China
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 316
- Registration Number
- NCT05885503
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China